

Zhihong Chi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9670950/publications.pdf>

Version: 2024-02-01

138
papers

2,220
citations

236833

25
h-index

276775

41
g-index

142
all docs

142
docs citations

142
times ranked

2775
citing authors

#	ARTICLE	IF	CITATIONS
1	EZH2 Inhibitor Enhances the STING Agonist-Induced Antitumor Immunity in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1158-1170.e8.	0.3	14
2	Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study*. <i>British Journal of Dermatology</i> , 2022, 186, 977-987.	1.4	9
3	Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 341-341.	0.8	0
4	Clinical characteristics of patients with collecting duct carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 297-297.	0.8	0
5	Prognostic value of HER2 expression levels for upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 557-557.	0.8	5
6	Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 515-515.	0.8	24
7	Impact of different HER2 expression levels on the outcomes of second-line immunotherapy for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 524-524.	0.8	1
8	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
9	Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 354-362.	0.9	4
10	OrienX010, an oncolytic virus, in patients with unresectable stage III-IV melanoma: a phase Ib study. , 2022, 10, e004307.		13
11	An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. <i>Annals of Surgical Oncology</i> , 2022, 29, 5221-5234.	0.7	15
12	ASO Visual Abstract: An Evidence-Based Staging System for Mucosal Melanoma: a Proposal. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
13	The association of Ki67 level and adjuvant treatment options in mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21582-e21582.	0.8	0
14	Phase Ib study of anlotinib in combination with anti-PD-L1 ab (TQB2450) in patients with advanced acral melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21543-e21543.	0.8	0
15	A phase Ia/Ib study evaluating the safety and efficacy of intratumorally administrated OH2, an oncolytic herpes simplex virus 2, in unresected stage IIIc to IV melanoma patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21537-e21537.	0.8	1
16	Analysis of overall survival (OS) and relapse-free-survival (RFS) in the phase Ib clinical trial of anti-PD-1 ab (toripalimab) plus intralesional injection of OrienX010 in stage III-IV melanoma with liver metastases.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9551-9551.	0.8	2
17	A phase I dose-escalation study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in combination with toripalimab in advanced melanoma and other solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14586-e14586.	0.8	0
18	Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4518-4518.	0.8	12

#	ARTICLE	IF	CITATIONS
19	A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM).. Journal of Clinical Oncology, 2022, 40, 9508-9508.	0.8	5
20	Adjuvant temozolomide plus cisplatin versus high-dose interferon alpha-2b in resected mucosal melanoma: A randomized, multicenter, controlled, phase III trial.. Journal of Clinical Oncology, 2022, 40, 9578-9578.	0.8	2
21	A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2022, 40, 4519-4519.	0.8	15
22	Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.. Journal of Clinical Oncology, 2022, 40, 4563-4563.	0.8	1
23	Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naïve unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.. Journal of Clinical Oncology, 2022, 40, 9512-9512.	0.8	2
24	Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 75.e1-75.e8.	0.8	9
25	Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy. Translational Oncology, 2021, 14, 100949.	1.7	6
26	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2021, 27, 43-51.	3.2	125
27	Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. Npj Genomic Medicine, 2021, 6, 7.	1.7	41
28	Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2731-2740.	1.2	3
29	Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology, 2021, 39, 881-889.	0.8	37
30	Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma.. Journal of Clinical Oncology, 2021, 39, 9539-9539.	0.8	2
31	Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy-Ad hoc Analyses of Pooled Data From Two Clinical Trials. Frontiers in Oncology, 2021, 11, 639085.	1.3	6
32	Clinicopathologic features of Xp11.2 translocation renal cell carcinoma and its response to target therapy.. Journal of Clinical Oncology, 2021, 39, e16559-e16559.	0.8	0
33	A phase 2 clinical trial of neoadjuvant anti-PD-1 ab (Toripalimab) plus axitinib in resectable mucosal melanoma.. Journal of Clinical Oncology, 2021, 39, 9512-9512.	0.8	9
34	A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma.. Journal of Clinical Oncology, 2021, 39, 9570-9570.	0.8	5
35	Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. European Journal of Cancer, 2021, 148, 297-306.	1.3	19
36	Four-year survival follow-up of toripalimab (JS001) as salvage therapy in Chinese melanoma patients.. Journal of Clinical Oncology, 2021, 39, e21522-e21522.	0.8	2

#	ARTICLE	IF	CITATIONS
37	RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.. Journal of Clinical Oncology, 2021, 39, 4534-4534.	0.8	10
38	Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma.. Journal of Clinical Oncology, 2021, 39, e18042-e18042.	0.8	1
39	Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase randomized trial.. Journal of Clinical Oncology, 2021, 39, 9573-9573.	0.8	4
40	Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials. Frontiers in Immunology, 2021, 12, 691032.	2.2	10
41	Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. Frontiers in Oncology, 2021, 11, 720044.	1.3	9
42	Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma. European Journal of Cancer, 2021, 156, 83-92.	1.3	7
43	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. Frontiers in Pharmacology, 2021, 12, 747416.	1.6	0
44	Surgical Outcomes of Vaginal or Cervical Melanoma. Frontiers in Surgery, 2021, 8, 771160.	0.6	1
45	The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. Frontiers in Oncology, 2020, 10, 546604.	1.3	15
46	Toripalimab for the treatment of melanoma. Expert Opinion on Biological Therapy, 2020, 20, 863-869.	1.4	15
47	Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine, 2020, 55, 102755.	2.7	12
48	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. Clinical Cancer Research, 2020, 26, 4250-4259.	3.2	104
49	The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma. Annals of Surgical Oncology, 2020, 27, 3478-3485.	0.7	29
50	A Functional Synonymous Variant in <i>PDGFRA</i> Is Associated with Better Survival in Acral Melanoma. Journal of Cancer, 2020, 11, 2945-2956.	1.2	8
51	Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.. Journal of Clinical Oncology, 2020, 38, 10007-10007.	0.8	11
52	A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma.. Journal of Clinical Oncology, 2020, 38, 10040-10040.	0.8	10
53	A first-in-human phase I/II study of HL-085, a MEK Inhibitor, in Chinese patients with NRASm advanced melanoma.. Journal of Clinical Oncology, 2020, 38, 10047-10047.	0.8	5
54	A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2020, 38, e17113-e17113.	0.8	9

#	ARTICLE	IF	CITATIONS
55	IBI310 monotherapy or in combination with sintilimab in patients with advanced melanoma: An open-label phase Ia/Ib study.. Journal of Clinical Oncology, 2020, 38, e15111-e15111.	0.8	1
56	Phase II study of apatinib combined with temozolomide in advanced melanoma patients after failure of anti-PD-1 therapy.. Journal of Clinical Oncology, 2020, 38, e22043-e22043.	0.8	1
57	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. Clinical Cancer Research, 2019, 25, 6511-6523.	3.2	62
58	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G ₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. Journal of Clinical Oncology, 2019, 37, 2987-2999.	0.8	126
59	Identification of a functional polymorphism within the 3' untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma. European Journal of Cancer, 2019, 118, 70-81.	1.3	13
60	Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing. Journal of Cancer, 2019, 10, 488-493.	1.2	8
61	miR-let-7b and miR-let-7c suppress tumorigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy. Journal of Experimental and Clinical Cancer Research, 2019, 38, 212.	3.5	53
62	RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma. Cell Death and Disease, 2019, 10, 254.	2.7	40
63	Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients. Thoracic Cancer, 2019, 10, 950-956.	0.8	27
64	MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways. Theranostics, 2019, 9, 945-960.	4.6	49
65	Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study. Oncology Research, 2019, 27, 495-501.	0.6	26
66	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. Journal of Hematology and Oncology, 2019, 12, 7.	6.9	113
67	Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations.. Journal of Clinical Oncology, 2019, 37, 9528-9528.	0.8	7
68	Tumor growth rate as an early indicator of the efficacy of anti-PD-1 immunotherapy in advanced melanoma.. Journal of Clinical Oncology, 2019, 37, e21050-e21050.	0.8	2
69	A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma (NCT02023710).. Journal of Clinical Oncology, 2019, 37, 9521-9521.	0.8	1
70	A clinical prognosis model for Asian advanced melanoma patients receiving immunotherapy.. Journal of Clinical Oncology, 2019, 37, e14081-e14081.	0.8	0
71	Mucosal melanoma staging and classification: Firstly established.. Journal of Clinical Oncology, 2019, 37, e21008-e21008.	0.8	0
72	Mucosal melanoma of the female genital tract: Operation modalities.. Journal of Clinical Oncology, 2019, 37, e21060-e21060.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Postoperative radiotherapy in resected sinonasal mucosal melanoma.. Journal of Clinical Oncology, 2019, 37, e21059-e21059.	0.8	0
74	Continuous intravenous infusion Rh-endostatin in combination with dacarbazine and cisplatin as the first-line therapy for metastatic melanoma.. Journal of Clinical Oncology, 2019, 37, e21007-e21007.	0.8	0
75	Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma. Human Pathology, 2018, 75, 137-145.	1.1	10
76	Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China. Annals of Surgical Oncology, 2018, 25, 885-893.	0.7	7
77	PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro. Cancer Biology and Therapy, 2018, 19, 584-589.	1.5	30
78	Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor. European Journal of Cancer, 2018, 89, 90-101.	1.3	19
79	Analysis of TSC1 mutation spectrum in mucosal melanoma. Journal of Cancer Research and Clinical Oncology, 2018, 144, 257-267.	1.2	12
80	High G2 and Sâ€phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis. Cancer Science, 2018, 109, 1787-1798.	1.7	19
81	Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. European Journal of Cancer, 2018, 100, 1-7.	1.3	31
82	Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure. Translational Oncology, 2018, 11, 1155-1159.	1.7	8
83	TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma. OncoTargets and Therapy, 2018, Volume 11, 4097-4104.	1.0	28
84	Increased <i>AURKA</i> Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma. Journal of Cancer, 2018, 9, 1267-1276.	1.2	7
85	Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. Journal of Hematology and Oncology, 2018, 11, 1.	6.9	196
86	Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients. Annals of Surgical Oncology, 2018, 25, 2184-2192.	0.7	34
87	A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma.. Journal of Clinical Oncology, 2018, 36, 9528-9528.	0.8	9
88	A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China.. Journal of Clinical Oncology, 2018, 36, 9539-9539.	0.8	12
89	Phase â€ randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.. Journal of Clinical Oncology, 2018, 36, 9589-9589.	0.8	18
90	Preliminary results from patients with metastatic urothelial carcinoma (UC) in a phase 2 study of JS001, an anti-PD-1 monoclonal antibody.. Journal of Clinical Oncology, 2018, 36, e16505-e16505.	0.8	3

#	ARTICLE	IF	CITATIONS
91	Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report. <i>Chinese Clinical Oncology</i> , 2018, 7, 62-62.	0.4	16
92	EZH2 copy number gain as a therapeutic target in mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21530-e21530.	0.8	1
93	Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9588-9588.	0.8	0
94	Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma. <i>Scientific Reports</i> , 2017, 7, 39597.	1.6	10
95	Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6946-6957.	3.2	73
96	Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. <i>Oncology Letters</i> , 2017, 14, 3601-3605.	0.8	25
97	<i>MAPK</i> Pathway and <i>TERT</i> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 6120-6127.	3.2	71
98	Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon. <i>Translational Oncology</i> , 2017, 10, 719-725.	1.7	27
99	Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma. <i>Oncology Letters</i> , 2017, 15, 1839-1844.	0.8	12
100	Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. <i>Journal of Translational Medicine</i> , 2017, 15, 243.	1.8	33
101	A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3067-3067.	0.8	1
102	A phase I clinical trial of CM082 (X-82) in combination with everolimus for treatment of metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4575-4575.	0.8	5
103	Natural killer cells as a predictive biomarker for response to anti-PD-1 therapy in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21055-e21055.	0.8	0
104	Multivariate analysis of prognostic factors among 706 mucosal melanoma patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9569-9569.	0.8	0
105	Efficacy and tolerability of vemurafenib in BRAF-mutant acral and mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21017-e21017.	0.8	4
106	OrienX010 oncolytic viral therapy in phase Ic trial of intralesional injection in liver metastases among patients with stage IV melanoma after standard treatment.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21013-e21013.	0.8	4
107	Whole genome and RNA sequencing reveal the distinct genomic landscape of acral melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9589-9589.	0.8	2
108	Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. <i>Oncotarget</i> , 2016, 7, 27044-27054.	0.8	28

#	ARTICLE	IF	CITATIONS
109	GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. <i>European Journal of Cancer</i> , 2016, 65, 156-163.	1.3	55
110	Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1018-1027.	3.2	69
111	OrienX010 oncolytic viral therapy in phase II trial of intralesional injection in unresected stage II acral melanoma patients in China.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21001-e21001.	0.8	2
112	Association of immune-inflammation index with outcome of high-risk acral melanoma patients treated with adjuvant high-dose interferon.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21070-e21070.	0.8	4
113	Imatinib versus interferon as adjuvant therapy in a phase II study in patients with highrisk C-Kit mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21073-e21073.	0.8	1
114	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Chinese Clinical Oncology</i> , 2016, 5, 57-57.	0.4	46
115	The expression and clinical significance of PD-L1 in patients with upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 444-444.	0.8	0
116	Sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 594-594.	0.8	0
117	A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710).. <i>Journal of Clinical Oncology</i> , 2016, 34, e21043-e21043.	0.8	0
118	Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9512-9512.	0.8	0
119	A prospective multicenter phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma (NCT01762150).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4559-4559.	0.8	0
120	Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients. <i>British Journal of Ophthalmology</i> , 2015, 99, 990-996.	2.1	46
121	Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9047-9047.	0.8	5
122	Preliminary results of a phase II trial with continuous intravenous infusion of rh-endostatin in combination with dacarbazine as the first-line therapy for metastatic acral melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20087-e20087.	0.8	1
123	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Annals of Translational Medicine</i> , 2015, 3, 322.	0.7	32
124	Genetic polymorphisms of PDGFR/VEGFR2/VEGFR3/RET and their relevance to thrombocytopenia in mRCC patients treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 481-481.	0.8	0
125	A phase II study of everolimus for advanced melanoma patients with mTOR mutations.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20007-e20007.	0.8	0
126	The efficacy and safety analysis of sunitinib plus temozolomide therapy in patients with metastatic mucosal melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20043-e20043.	0.8	0

#	ARTICLE	IF	CITATIONS
127	Effect of nanosecond pulsed electric fields in combination with everolimus on melanoma.. Journal of Clinical Oncology, 2015, 33, e20102-e20102.	0.8	0
128	Clinical presentation, systemic therapy and prognosis of mucosal melanoma, a study of 463 consecutive cases.. Journal of Clinical Oncology, 2015, 33, e20036-e20036.	0.8	0
129	Analysis of mTOR Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.. Journal of Clinical Oncology, 2015, 33, 9049-9049.	0.8	0
130	A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).. Journal of Clinical Oncology, 2015, 33, e15591-e15591.	0.8	0
131	A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma.. Journal of Clinical Oncology, 2015, 33, e20076-e20076.	0.8	0
132	Comparison of clinical presentation and prognosis between acral cutaneous melanoma and non-acral cutaneous melanoma.. Journal of Clinical Oncology, 2015, 33, e20008-e20008.	0.8	0
133	Outcome of isolated limb infusion (ILI) treatment for Chinese acral melanoma patients with/without gene mutations.. Journal of Clinical Oncology, 2014, 32, e20014-e20014.	0.8	0
134	Primary malignant melanoma of the esophagus: Clinical features, signaling pathway, management, and survival.. Journal of Clinical Oncology, 2014, 32, e20015-e20015.	0.8	0
135	Effect of restoration of microRNA-18a on improvement of imatinib therapy on secondary imatinib-resistance metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 9040-9040.	0.8	0
136	Salvage therapy for metastatic acral or mucosal melanoma: Efficacy and safety analysis of nab-paclitaxel/carboplatin combined with bevacizumab in c-kit/BRAF wild-type pts.. Journal of Clinical Oncology, 2014, 32, e20017-e20017.	0.8	0
137	A pilot, open-label phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma.. Journal of Clinical Oncology, 2014, 32, e15554-e15554.	0.8	0
138	Prognostic factors for disease-free survival of ethnic Chinese patients with ocularmelanoma.. Journal of Clinical Oncology, 2014, 32, e20016-e20016.	0.8	0